Hepatitis C virus (HCV) is the major agent of transfusionassociated and community-acquired non-A, non-B hepatitis. Thus, commercial assays for detecting anti-HCV antibodies are extensively used for diagnostic and epidemiologic purposes (5, 6, 11) . However, there is still limited information on whether the results of such assays are influenced by the genetic variability observed among HCV strains (1, 4, 7) . The problem is of interest because, on the basis of genetic diversity, HCV isolates have been grouped into five or six genotypes depending on the classification system used (2, 3, 12, 16) , and there have been suggestions that a number of features of HCV infection, including severity of the pathological changes produced, may depend on HCV genotype (14, 15, 18) . In the present study, we examined the sera of patients infected with different HCV genotypes to evaluate whether they behave differently when tested with currently available anti-HCV immunoblotting assays. In addition, the sera were examined for the presence of anti-GOR antibody (9, 10) , which has been proposed as a marker of HCV infection severity (8) . As the GOR epitope is a nuclear antigen that shares a short amino acid sequence with the core protein of HCV, anti-GOR antibodies are believed to represent HCV-induced autoantibodies (10) .
The 124 patients selected for the study (28 hemophiliacs and 96 patients with community-acquired infection; 74 males and 50 females aged 12 to 84 years) were all positive for anti-HCV antibody by second-generation enzyme-linked immunosorbent assay (ELISA; Ortho, Milan, Italy) and negative for human immunodeficiency virus antibody (recombinant human immunodeficiency viruses types 1 and 2; Abbott, Chicago, Ill.) and were viremic by nested reverse transcriptase PCR with universal primers covering the conserved 5Ј-untranslated region of the HCV genome, as described previously (17) . Genotyping was performed by nested reverse transcriptase PCR according to the method of Okamoto et al. (12) , using primers derived from the core region exactly as described before (14) . Genotype I was present in 30 subjects; genotype II, in 66; genotype III, in 10; and genotype IV, in 18. Six additional patients were excluded from subsequent serological analysis because the HCV they harbored proved unclassifiable both by the above method and using a primer set that recognizes Okamoto's genotype V (13) . All sera were examined blindly by secondgeneration recombinant immunoblot assay (RIBA; RIBA-2 [Ortho]), third-generation RIBA (RIBA-3; Ortho), secondgeneration line immunoblot assay (LIA; LIA-2 [Sorin Biomedica, Saluggia, Italy]), and third-generation LIA (LIA-3; Sorin Biomedica). Both RIBA and LIA are strip assays containing distinct bands coated with recombinant or synthetic HCV antigens. The tests were performed according to the manufacturer's instructions on sera aliquoted immediately after collection and stored at Ϫ80ЊC until tested.
The results of the immunoblotting assays are summarized in Tables 1 to 3 with the following criteria, adopted after we ascertained that they did not affect the general conclusions of the study: (i) if the assay contained more than one antigen derived from a given viral region, the patient was scored as seropositive for that region even when it reacted to one of such antigens only; (ii) only serological profiles with an overall frequency of 20% or higher in the entire population of patients examined are presented; and (iii) serum samples reactive with one viral region only were scored as indeterminate.
RIBA-2 includes four recombinant viral peptides derived from the nonstructural regions NS3 (antigen c33c) and NS4 (antigens 5-1-1 and c100-3) and from the structural core region (antigen c22-3). Patients infected with genotypes I and II exhibited significantly higher frequencies of complete reactivity (i.e., positivity to all viral regions included in the assay) than patients infected with genotypes III and IV (Table 1 ). Such a difference was mainly due to a low prevalence of antibodies to the NS4 region in the latter patients (Table 2 ). With RIBA-2, indeterminate results numbered eight and were found in all genotype groups except genotype I (Table 3) .
In RIBA-3, a large recombinant fragment of the NS5 region has been added, and with the exception of c33c, the other antigens are represented by synthetic peptides. With this assay, there were no significant differences in the prevalence of serological profiles found in patients infected with different HCV genotypes (Table 1) , and the reactivity to the NS4 region was higher for all genotypes than with RIBA-2 ( Table 2 ). The number of indeterminate results was two ( Table 3) .
The antigens in LIA-2 are synthetic peptides derived from the NS4 and NS5 regions (one peptide each) and from the core region (four peptides), whereas the antigens in LIA-3 are five synthetic peptides derived from the NS1, NS4, and NS5 regions (one peptide each) and the core region (two peptides) and a recombinant NS3 antigen. With both assays, complete reactivities were more frequent in patients infected with genotype I than in patients harboring the other genotypes (Table 1) . Again, the largest differences in prevalence were observed with the NS4 antigen ( Table 2) . Indeterminate results totaled 23 with LIA-2 (most frequent among genotype IV-infected individuals) and 2 with LIA-3 ( Table 3) . Anti-GOR antibody was assayed by using an immunoglobulin G ELISA based on a synthetic peptide (Medical Systems, Genoa, Italy). The overall reactivity was 68%, and the prevalence was significantly lower in patients infected with genotype IV than in the other patients (Table 4) .
In summary, these results indicate that (i) in currently available HCV immunoblotting assays, patients infected with different HCV genotypes tend to have different serological profiles. (ii) This is mainly due to a low prevalence of antibodies to viral region NS4 in patients infected with genotypes III and IV. (iii) Finally, the differences are more evident with second-than with third-generation assays. It is likely that the variations in anti-NS4 antibody prevalence observed in the patient groups are a reflection of the marked diversity in amino acid composition of the NS4 region of the different HCV genotypes (16) . On the other hand, the fact that with thirdgeneration assays the prevalence of antibodies observed is generally higher than that with second-generation assays is probably due to the incorporation in the immunoblotting strips of different segments of the various viral regions (for example, region NS4 is represented by a synthetic peptide of 16 amino acids in RIBA-3 and by a recombinant antigen of 63 amino acids in RIBA-2), although the amount of antigens incorporated and other factors might also be important. In any case, the fact that even with second-generation assays no serological profile was specific for a given HCV genotype and previous observations showing that the immunological status of the host may also influence the spectrum of anti-HCV antibodies found in patients (17) rule out the possibility of drawing a firm conclusion about the infecting genotype from immunoblotting data. The advantage in this direction provided by secondgeneration assays is largely counterbalanced by the lower number of indeterminate results obtained with third-generation assays, which are therefore to be preferred for diagnostic a Prevalence significantly different from genotype IV (chi-square test; P Ͻ 0.05).
b Prevalence significantly different from genotypes III and IV (P Ͻ 0.05 and P Ͻ 0.01, respectively).
c Prevalence significantly different from the other genotypes (P Ͻ 0.05, P Ͻ 0.05, and P Ͻ 0.01 with genotypes II, III, and IV, respectively).
d Prevalence significantly different from the other genotypes (P Ͻ 0.001, P Ͻ 0.01, and P Ͻ 0.001 with genotypes II, III, and IV, respectively). II  97  NA  95  74  NA  III  90  NA  70  50  NA  IV  100  NA  89  33  NA   RIBA-3  I  100  NA  100  97  77  II  97  NA  100  94  57  III  90  NA  100  70  70  IV  100  NA  94  72  61   LIA-2  I  97  NA  NA  87  63  II  97  NA  NA  76  42  III  90  NA  NA  30  50  IV  100  NA  NA  44  28   LIA-3  I  97  97  100  97  67  II  98  54  95  91  46  III  90  55  44  89  78  IV  100  69  75  50  31 a Numbers of patients examined for each genotype are given in Table 1 . b NA, not applicable. purposes. The present results also show that patients infected by genotype IV exhibit a lower prevalence of anti-GOR antibody. This is of interest because it might indicate a tendency of this genotype to produce milder liver damage than other genotypes. In previous studies, patients with more severe liver damage showed a significantly higher prevalence of genotype II than patients with persistent chronic hepatitis (12, 14, 15, 18) .
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